Omeros (OMER) Other Non Operating Income (2010 - 2026)
Omeros recorded quarterly Other Non Operating Income of $73.1 million in Q1 2026, down 45.49% quarter-over-quarter from $134.2 million in Q4 2025, and up 112632.31% year-over-year from N/an in Q1 2025.
Omeros' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $73.1 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 112632.31% year-over-year to $73.1 million; the TTM figure through Mar 2026 stood at $208.1 million (up 452591.3% YoY), while the FY2025 annual figure was -$136.7 million, down 719663.16% from the prior year.
- Other Non Operating Income came in at $73.1 million for Q1 2026 at Omeros, down from $134.2 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $134.2 million in Q4 2025 to a low of -$65000.0 in Q1 2025.
- A 5-year average of $26.7 million and a median of $735000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income plunged 99.54% in 2024 and surged 706215.79% in 2025, its largest moves.
- Omeros' Other Non Operating Income stood at $670000.0 in 2022, then soared by 511.94% to $4.1 million in 2023, then slumped by 99.54% to $19000.0 in 2024, then soared by 706215.79% to $134.2 million in 2025, then plunged by 45.49% to $73.1 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $73.1 million, $134.2 million, and $800000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.15 Mn |
| Dec 31, 2025 | 134.20 Mn |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | -65,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 4.10 Mn |
| Jun 30, 2022 | 670,000.00 |
| Mar 31, 2022 | 493,000.00 |
| Dec 31, 2021 | 526,000.00 |
| Sep 30, 2021 | 461,000.00 |
| Jun 30, 2021 | 333,000.00 |
| Mar 31, 2021 | 418,000.00 |
| Sep 30, 2020 | -13.37 Mn |
| Jun 30, 2020 | 364,000.00 |
| Mar 31, 2020 | 549,000.00 |
| Dec 31, 2019 | 292,000.00 |
| Sep 30, 2019 | 353,000.00 |
| Jun 30, 2019 | 415,000.00 |
| Mar 31, 2019 | 494,000.00 |
| Dec 31, 2018 | -14.62 Mn |
| Sep 30, 2018 | 572,000.00 |
| Jun 30, 2018 | 597,000.00 |
| Mar 31, 2018 | 460,000.00 |
| Dec 31, 2017 | 434,000.00 |
| Sep 30, 2017 | 408,000.00 |
| Jun 30, 2017 | 303,000.00 |
| Mar 31, 2017 | 299,000.00 |
| Dec 31, 2016 | -6.27 Mn |
| Sep 30, 2016 | 211,000.00 |
| Jun 30, 2016 | 174,000.00 |
| Mar 31, 2016 | 288,000.00 |
| Dec 31, 2015 | -1.30 Mn |
| Sep 30, 2015 | 251,000.00 |
| Jun 30, 2015 | 224,000.00 |
| Mar 31, 2015 | 218,000.00 |
| Dec 31, 2014 | 372,000.00 |
| Sep 30, 2014 | -251,000.00 |
| Jun 30, 2014 | 165,000.00 |
| Mar 31, 2014 | -286,000.00 |
| Dec 31, 2013 | -421,000.00 |
| Sep 30, 2013 | 154,000.00 |
| Jun 30, 2013 | 155,000.00 |
| Mar 31, 2013 | 112,000.00 |
| Dec 31, 2012 | 160,000.00 |
| Sep 30, 2012 | 159,000.00 |
| Jun 30, 2012 | 152,000.00 |
| Mar 31, 2012 | -341,000.00 |
| Dec 31, 2011 | 171,000.00 |
| Sep 30, 2011 | 171,000.00 |
| Jun 30, 2011 | 171,000.00 |
| Mar 31, 2011 | 184,000.00 |
| Dec 31, 2010 | -902,000.00 |
| Sep 30, 2010 | 189,000.00 |
| Jun 30, 2010 | 218,000.00 |